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Abstract
Background: The human anterior cruciate ligament (hACL) and medial collateral ligament (hMCL) of the knee joint
are frequently injured, especially in athletic settings. It has been known that, while injuries to the MCL typically heal
with conservative treatment, ACL injuries usually do not heal. As adult stem cells repair injured tissues through
proliferation and differentiation, we hypothesized that the hACL and hMCL contain stem cells exhibiting unique
properties that could be responsible for the differential healing capacity of the two ligaments.
Methods: To test the above hypothesis, we derived ligament stem cells from normal hACL and hMCL samples
from the same adult donors using tissue culture techniques and characterized their properties using
immunocytochemistry, RT-PCR, and flow cytometry.
Results: We found that both hACL stem cells (hACL-SCs) and hMCL stem cells (hMCL-SCs) formed colonies in
culture and expressed stem cell markers nucleostemin and stage-specific embryonic antigen-4 (SSEA-4). Moreover,
both hACL-SCs and hMCL-SCs expressed CD surface markers for mesenchymal stem cells, including CD44 and
CD90, but not those markers for vascular cells, CD31, CD34, CD45, and CD146. However, hACL-SCs differed from
hMCL-SCs in that the size and number of hACL-SC colonies in culture were much smaller and grew more slowly
than hMCL-SC colonies. Moreover, fewer hACL-SCs in cell colonies expressed stem cell markers STRO-1 and
octamer-binding transcription factor-4 (Oct-4) than hMCL-SCs. Finally, hACL-SCs had less multi-differentiation
potential than hMCL-SCs, evidenced by differing extents of adipogenesis, chondrogenesis, and osteogenesis in the
respective induction media.
Conclusions: This study shows for the first time that hACL-SCs are intrinsically different from hMCL-SCs. We
suggest that the differences in their properties contribute to the known disparity in healing capabilities between
the two ligaments.
Background
The human anterior cruciate ligament (hACL) and med-
ial collateral ligament (hMCL) are two major ligaments
that function to stabilize the knee joint. Because knee
joints are subjected to large mechanical loads, particu-
larly in athletic settings, both ligaments are frequently
injured. It has been established that the injured hACL
rarely heals, often requiring surgical reconstruction. As
a result, patients with injured ACLs typically experience
recurrent instability of the knee joint [1], which could
lead to development of osteoarthritis [2]. On the other
hand, the injured hMCL typically heals with conserva-
tive, non-operative treatment [3,4].
Several theories have been proposed as to why this dif-
ference in healing capability exists between the ACL and
MCL. These include intra-articular versus extra-articular
environments, different mechanical environments [5,6],
and differences in nitric oxide synthesis [7], vascular sup-
ply [8], and proliferative potential of fibroblasts [9,10]. In
recent years, however, the importance of adult stem cells
(ASCs) in tissue healing has been noted [11-13]. ASCs
are characterized in vitro by their remarkable abilities to
proliferate extensively in an uncommitted state (self-
renewal) and differentiate into cell types of various tissue
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any medium, provided the original work is properly cited.lineages (multi-potential), including adipocytes, chondro-
cytes, and osteocytes. ASCs are responsible for repair and
regeneration of injured tissues by proliferation and differ-
entiation. Multipotent ASCs have been found in various
types of tissues including bone marrow [14], adipose tis-
sue [15,16], umbilical cord [17], synovium [18], spinal
cord [19], dental pulp [20], and periodontal ligaments
[21]. Recently, human, mouse, and rabbit tendons were
found to contain stem cells, and these tendon stem cells
(TSCs) exhibit the three universal characteristics of
ASCs: clonogenicity, self-renewal, and multi-differentia-
tion potential [22,23]. Therefore, we inferred that hACL
and hMCL also contain ASCs. Indeed, a previous study
showed that cells derived from young rabbit ACLs and
MCLs exhibit stem cell properties [24].
Because ASCs are responsible for repair and regenera-
tion of injured tissues, and because injured ACLs and
MCLs have differential healing capacities as noted above,
we hypothesized in this study that both human ACLs
and MCLs contain ASCs, but that they exhibit distinctive,
ligament-specific properties. To test this hypothesis, we
derived stem cells from normal human ACL and MCL
samples from the same donors. We then characterized
and compared the properties of the two types of ligament
stem cells, denoted hACL-SCs and hMCL-SCs, respec-
tively. Herein we report the findings of this study.
Methods
hACL and hMCL stem cell cultures
Human ACL and MCL tissue samples free of pathology
were obtained from six adult donors ranging in age
from 20 to 36 years old (Table 1). The protocol for
obtaining the ligament tissue samples was approved by
the University of Pittsburgh Institutional Review Board.
To prepare the tissue cultures, the ligament sheath was
removed to obtain the core portion of the ligament,
which was then minced into small pieces, and each 100
mg of wet tissue samples were digested in 1 ml of PBS
c o n t a i n i n g3m go fc o l l a g e n a s et y p eIa n d4m go fd i s -
pase as described previously [23]. Single cell suspensions
were cultured in either a 96 well plate (1 cell/well) or
T25 flasks (4 × 10
5/flask). After eight to ten days in cul-
ture, hACL-SCs and hMCL-SCs formed distinct colonies
on the plastic surfaces of the plates or flasks. The
colonies were visualized with methyl violet and then
counted with a hemocytometer.
Trypsin was locally applied to each colony under
microscopic visualization in order to detach stem cell
colonies, and detached cells were collected and trans-
ferred to T25 flasks for further culture. The growth
medium consists of Dulbecco’s modified Eagle’s medium
(DMEM; Lonza, Walkersville, MD) supplemented with
20% fetal bovine serum (FBS; Atlanta Biologicals,
Lawrenceville, GA), 100 μM 2-mercaptoethanol (Sigma-
Aldrich, St Louis), 100 U/ml penicillin, and 100 μg/ml
streptomycin (Atlanta Biologicals, Lawrenceville, GA).
To measure the proliferative capacities of hACL-SCs
and hMCL-SCs, we used population doubling time
(PDT) as an index. Briefly, hACL-SCs or hMCL-SCs
were seeded in 6-well plates at a density of 6 × 10
4/well
and cultured with growth medium until confluence. The
PDT is calculated by dividing the total culture time by
the number of generations [23].
Expression of stem cell markers by hACL-SCs and
hMCL-SCs
Immunocytochemistry was used to assay for expression
of the following stem cell markers: nucleostemin, Oct-4,
STRO-1, and SSEA-4. To perform immunostaining,
hACL-SCs or hMCL-SCs were seeded in 12-well plates
at a density of 3.5 × 10
4/well and cultured with growth
medium for 3 days. The medium was then removed,
and the cells were washed with PBS once. The stem
cells were first fixed in 4% paraformaldehyde in phos-
phate-buffered saline (PBS) for 20 minutes. For nucleos-
temin and Oct-4 staining, this step was followed by
washing with 0.1% Triton-X100 for 15 minutes. All cells
were then blocked with 3% mouse serum for 1 hour. In
the first antibody reaction, the stem cells were incubated
with either mouse anti-human STRO-1 (1:400, Cat. #39-
8401, Invitrogen, Carlsbas, CA), mouse anti-human
SSEA-4 (1:400, Cat. #414000, Invitrogen, Carlsbas, CA),
goat anti-human nucleostemin (1:350, Cat. # GT15050,
Neuromics, Edina, MN), or rabbit anti-human Oct-3/4
(1:350, Cat. # sc-9081, Santa Cruz Biotechnology, Santa
Cruz, CA) at room temperature for 2 hours. After wash-
ing the cells with PBS, cyanine 3 (Cy3)-conjugated goat
anti-mouse immunoglobulin G (IgG) secondary antibody
(1:500, Cat.# A10521, Invitrogen, Catlsbas, CA) was
applied at room temperature for 1 hour to STRO-1 and
SSEA-4 samples while Cy3-conjugated donkey anti-goat
IgG secondary antibody (1:500, Cat.# AP180C, Millipore,
Temecula, CA) was used for nucleostemin and Cy-3
conjugated goat anti-rabbit IgG antibody (1:400, Cat. #
AP132C, Millipore, Temecula, CA) was used for Oct-3/
4 samples at room temperature for 2 hours. The cells
were also counterstained with Hoechst 33342 (Cat. #
33270; Sigma, St Louis).
Table 1 Human ACL and MCL samples
Donor Age Race Gender
1 26 Caucasian M
2 27 Black M
3 26 Black F
4 36 Caucasian M
5 20 Hispanic M
6 29 Black F
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CD90, CD34, CD45, and CD146 were stained in parallel
by immunocytochemistry. Fixed cells were incubated
with fluorescein isothiocyanate (FITC)- or Cy3- or phy-
coerythrin (PE)-conjugated mouse anti-human antibo-
dies (1:400) for 1 hour. All steps were performed at
room temperature. Unless otherwise noted, all antibo-
dies were purchased from Chemicon International
(Temecula, CA), BD Pharmingen (BD Biosciences;
http://bdbiosciences.com), or Santa Cruz Biotechnology
(Santa Cruz, CA). Fluorescent images of the stained
cells were taken by a CCD camera on an inverted fluor-
escent microscope (Nikon eclipse, TE2000-U) using
SPOT™ imaging software (Diagnostic Instruments, Inc.,
Sterling Heights, MI).
Multi-differentiation potentials of hACL-SCs and
hMCL-SCs
The multi-differentiation potentials of hACL-SCs and
hMCL-SCs were examined in vitro to determine
whether they could undergo adipogenesis, chondrogen-
esis, and osteogenesis. Cells at passage 1 were seeded in
a 6-well plate at a density of 2.4 × 10
5 cells/well in basic
growth medium consisting of low glucose DMEM, 10%
heat inactivated FBS, 100 U/ml penicillin, and 100 μg/
ml streptomycin. After reaching confluence, cells for
adipogenesis were cultured in adipogenic induction
medium (Millipore, Cat. # SCR020) consisting of basic
growth medium supplemented with 1 μM dexametha-
sone, 10 μg/ml insulin, 100 μM indomethacin, and 0.5
mM isobutylmethylxanthine (IBMX) for 21 days. Oil
Red O assay was used to detect lipid droplets contained
in the differentiated adipocytes.
For chondrogenesis, confluent stem cells were cultured
in chondrogenic induction medium consisting of basic
growth medium along with 40 μg/ml proline, 39 ng/ml
dexamethasone, 10 ng/ml transforming growth factor beta
3( T G F - b3), 50 μg/ml ascorbate 2-phosphate, 100 μg/ml
sodium pyruvate, and 50 mg/ml ITS premix (BD, Cat. #
354350). After 21 days in culture, the glycosaminoglycans
(GAG)-rich matrix produced by differentiated chondro-
cytes was stained using the Safranin O assay.
Finally, for osteogenic differentiation, stem cells were
cultured in osteogenic induction medium consisting of
basic growth medium with 0.1 μM dexamethasone, 0.2
mM ascorbic 2-phosphate, and 10 mM glycerol 2-phos-
phate for 21 days. The differentiated cells released cal-
cium-rich deposits, which were stained by the Alizarin
Red S assay. Cells cultured in basic growth medium for
the same durations were used as a control.
Oil Red O assay
After discarding the medium, the cells were washed 3
times for 5 minutes each with PBS. The cells were then
fixed in 4% paraformaldehyde for 40 minutes at room
temperature. Subsequently, the cells were washed 3
times with PBS at 5 minute intervals and then with
water twice for 5 minutes each. Finally, the cells were
incubated with 0.36% Oil Red O solution (Millipore,
Cat. # 90358) for 50 minutes, followed by washing 3
times with water.
Safranin O assay
The cells were fixed in ice-cold ethanol for 1 hour,
rinsed with distilled water twice for 5 minutes each, and
stained with Safranin O solution (Sigma, Cat. # HT904)
for 30 minutes. The cells were then rinsed five times
with distilled water.
Alizarin Red S assay
The cells cultured in osteogenic medium were fixed in
chilled 70% ethanol for 1 hour, rinsed with distilled
water for 5 minutes twice, and stained with Alizarin Red
S solution (Millipore, Cat. # 2003999) for 30 minutes at
room temperature. The cells then underwent five rinses
with distilled water. Cells stained with the three assays
were examined, and images were taken and analyzed on
an inverted fluorescent microscope as noted earlier.
Semi-quantification of the extent of cell differentiation
Briefly, 12 views from each well were randomly chosen
on a microscope with a magnification of 20×. Then, the
areas of positive staining were identified manually and
computed by SPOT IMAGING Software. Next, the pro-
portion of positive staining was calculated by dividing
the stained area by the view area. Twelve ratio values
for each of three wells were averaged to obtain the per-
centage of positive staining, which represents the extent
of cell differentiation in the respective induction
medium.
Flow cytometry (FACS) analysis
The cell suspension (2.5 × 10
6 in 50 μl PBS) was incu-
bated with 20 μl of the appropriate serum in a round-
bottomed tube at 4°C for 30 minutes. Subsequently, 2 μl
o fp r i m a r ya n t i b o d y( 0 . 2m g / m ls t o c ks o l u t i o n )w a s
added and incubated at 4°C for 1 hour. The cells were
then washed three times with 2% FBS-PBS and reacted
with 1 μl of secondary antibody (1 mg/ml stock solu-
tion) at 4°C for 1 hour. Afterwards the cells were
washed twice with PBS and then fixed with 0.5 ml of 1%
paraformaldehyde. FACS analysis was performed with
BD LSR II Flow Cytometer (BD Biosciences, http://
www.bdbiosciences.com).
Gene expression analysis by RT-PCR
RNA was extracted from hACL-SCs and hMCL-SCs
using the RNeasy Mini Kit with an on-column DNase I
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from 1 μg total RNA, which was synthesized in a 20 μl
reaction by reverse transcription using SuperScript II
(Invitrogen). The following conditions for cDNA synth-
esis were applied: 65°C for 5 minutes and cooling for 1
minute at 4°C, then 42°C for 50 minute and 72°C for 15
minute. Next, qRT-PCR was performed using QIAGEN
QuantiTect SYBR Green PCR Kit (QIAGEN). In a 50
μl PCR reaction mixture, 2 μl cDNA (total 100 ng
RNA) were amplified in a Chromo 4 Detector (MJ
Research, Maltham, MA) with incubation at 94°C for
5 minutes, followed by 30 to 40 cycles of a three tem-
perature program of 1 minute at 94°C, 30 seconds at
57°C, and 30 seconds at 72°C. The PCR reaction was
terminated after a 10 minute extension at 70°C and
stored at 4°C until analysis. The following human-spe-
cific primers based on previous publications were used:
Oct-4, STRO-1, peroxisome proliferator-activated
receptor gamma (PPARg, lipoprotein lipase (LPL), Sox-9,
collagen type II (Coll. II), Runx2, and alkaline phosphatase
(ALP). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) served as an internal control (Table 2). All
primers were synthesized by Invitrogen. The products
(each 5 μl) from qRT-PCR were run on a 2% agarose
gel in 0.5×TBE buffer at 100 V. The separated DNA
fragments were analyzed by a gel documentation sys-
tem (Bio-Rad).
Data Analysis
For each experimental condition, at least three replicates
were performed. The results presented in the figures are
representative of these (mean ± SD, n = 3 to 6). Two-tailed
student t-test was used for statistical analysis. A
P-value less than 0.05 was considered to be signifi-
cantly different.
Results
Clonogenicity and growth capacity of hACL-SCs and
hMCL-SCs
After three days in culture, cells from single cell suspen-
sions of both hACL and hMCL tissue samples attached
to plate surfaces and formed colonies. However, the
number and size of cell colonies from hACL-SCs and
hMCL-SCs were markedly different: colonies formed by
hACL-SCs were fewer in number (Figure 1A, B) and
smaller in size than those of hMCL-SCs (Figure 1C, D).
Moreover, hACL-SCs grew much more slowly than
hMCL-SCs, as the PDT for hACL-SCs was nearly dou-
ble that of hMCL-SCs (Figure 2).
Stem cell marker expression of hACL-SCs and hMCL-SCs
Using immunocytochemistry, both hACL-SCs and hMCL-
SCs were found to express nucleostemin (Figure 3A, B),
SSEA-4 (Figure 3D, E), CD44 (Figure 3G, H), and CD90
(Figure 3J, K). There was no significant difference
in nucleostemin expression between hACL-SCs and
hMCL-SCs, and more than 95% of both stem cells stained
positively for nucleostemin (Figure 3C). However, only
40% of hACL-SCs were positively stained by SSEA-4,
whereas more than 56% of hMCL-SCs were positive
stained (Figure 3F). Similarly, about 42% of hACL-SCs
expressed CD44 compared to about 60% for hMCL-SCs
(Figure 3I). Furthermore, both hACL-SCs and hMCL-SCs
expressed high levels of CD 90 (Figure 3L). Immunostain-
ing for CD31, CD34, CD45, and CD146 was negative (data
not shown).
Moreover, hACL-SCs stained weakly for STRO-1,
whereas more than 95% of hMCL-SCs stained positive
for STRO-1 (Figure 4A). The gene expression level of
STRO-1 in hACL-SCs was much lower than in hMCL-
SCs (Figure 4B). Similarly, fewer than 40% of hACL-SCs
expressed Oct-4, but more than 90% of hMCL-SCs
stained positive for Oct-4 (Figure 4C). Finally, hACL-
SCs expressed much lower levels of the Oct-4 gene than
hMCL-SCs (Figure 4D).
In addition, FACS analysis results showed that the
percentages of CD31, CD34, CD45, and CD146 positive
cells were less than 2%. Moreover, while CD44, CD90,
and SSEA-4 were expressed to a greater extent by both
hACL-SCs and hMCL-SCs (Figure 5), there was a signif-
icant difference in the level of expression between the
two types of stem cells (Table 3).
Self-renewal of hACL-SCs and hMCL-SCs
Both hACL-SCs and hMCL-SCs were able to undergo self-
renewal, indicated by the maintenance of a cobblestone
Table 2 Primers used for RT-PCR analysis
Gene Primer sequence Reference
PPARY 5’-GCT GTT ATG GGT GAA ACT CTG-3’
5’-CTC GGA CGT AGA GGT GGA ATA-3’
Risbud MV, et al.
2007
LPL 5’-GAG ATT TCT CTG TAT GGC ACC-3’
5’-CTG CAA ATG AGA CAC TTT CTC-3’
Risbud MV, et al.
2007
SOX-9 5’-ATC TGA AGA AGG AGA GCG AG-3’
5’-TCA GAA GTC TCC AGA GCT TG-3’
Risbud MV, et al.
2007
Collagen II 5’-TTT CCC AGG TCA AGA TGG TC-3’
5’-TCA CCT GGT TTT CCA CCT TC-3’
Risbud MV, et al.
2007
Runx2 5’-ACG ACA ACC GCA CCA TGG T-3’
5’-CTG TAA TCT GAC TCT GTC CT-3’
Risbud MV, et al.
2007
ALP 5’-TGG AGC TTC AGA AGC TCA ACA
CCA-3’
5’-ATC TCG TTG TCT GAG TAC CAG
TCC-3’
Risbud MV, et al.
2007
Oct-4 5’-GTG GTG GTA CGG GAA ATC AC-3’
5’-TAG CCA GGT TCG AGA ATC CA-3’
Huangfu D, et al.
2008
STRO-1 5’-GAA GCT AAA GTG GAT TCA GGA
GTA-3’
5’-TAA GCA GGG GAC CAT TAC A-3’
Rada T, et al.
2010
GAPDH 5’-GGG CTG CTT TTA ACT CTG GT-3’
5’-TGG CAG GTT TTT CTA GAC GG-3’
Risbud MV, et al.
2007
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Page 4 of 14shape after repetitive passage and expression of stem cell
markers nucleostemin and SSEA-4.
However, after five passages and two months in cul-
ture, hACL-SCs became elongated (Figure 6A), a typi-
cal fibroblast phenotype, and lost expression of
nucleostemin and SSEA-4 (Figure 6C, E), indicating
that they had undergone differentiation. In contrast,
hMCL-SCs, even after 13 passages and two months of
culture time, maintained a cobblestone shape (Figure 6B)
and expressed a high level of nucleostemin and SSEA-4
(Figure 6D, F). The extent of nucleostemin expression at
this passage, however, was lower than that at passage 1
(Figure 3).
Multidifferentiation potential of hACL-SCs and hMCL-SCs
After 21 days in adipogenic media, both hACL-SCs and
hMCL-SCs expressed high levels of PPARg and LPL (lipo-
protein lipase), two adipogenesis markers, indicating that
the cells had differentiated into adipocytes (Figure 7A).
W h e ng r o w ni nc h o n d r o g e n i c media, these ligament
stem cells differentiated into chondrocytes, evidenced by
upregulation of Sox-9 and Collagen type II expression
Figure 1 Colony formation by hACL-SCs and hMCL-SCs. A. hACL-SC colonies. B. hMCL-SC colonies. It is evident that hACL-SCs formed fewer
colonies than hMCL-SCs. C. A sample colony of hACL-SCs. D. A sample colony of hMCL-SCs. Notably, the hACL-SC colony is much smaller than
the hMCL-SC colony. Note that the results shown here were obtained from a 27-year-old male donor. (Bar: 100 μm).
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Page 5 of 14(Figure 7B), which are two markers for chondrogenesis.
Finally, both hACL-SCs and hMCL-SCs in osteogenic
media differentiated into osteocytes, as two osteogenesis
markers Runx2 and ALP were significantly upregulated
(Figure 7C).
Using respective histochemical staining, we further
demonstrated that both hACL-SCs and hMCL-SCs dif-
ferentiated into adipocytes, chondrocytes, and osteocytes
in the respective induction medium, evidenced by for-
mation of lipid droplets (Figure 8A), glycosaminoglycans
(GAG)-rich matrix (Figure 8C), and calcium-rich depos-
its (Figure 8E). Of note is that these stem cells could
form cartilage-like pellets in chondrogenic induction
medium (insets, Figure 8C). Semi-quantification of
stained areas showed that there were significant differ-
ences in the extent of adipogenesis (Figure 8B), chon-
drogenesis (Figure 8D), and osteogenesis (Figure 8F)
between hACL-SCs and hMCL-SCs.
Discussion
Adult stem cells were isolated and identified from
hACLs and hMCLs. We showed that these hACL-SCs
Figure 3 The expression of stem cell markers in hACL-SCs and hMCL-SCs. Both types of ligament stem cells expressed nucleostemin (A, B,
C), SSEA-4 (D, E, F), CD44 (G, H, I), and CD90 (J, K, L), but not CD31, CD34, CD45, and CD146 (not shown). Note that negative controls
(omission of primary antibodies) were also used in the immunostaining, and no staining signals were seen (data not shown). Also, the results
shown here were obtained from a of 26-year-old male donor (see Table 1). The passage 1 cells were used in immunostaining. (Bar: 100 μm).
Figure 2 The population doubling times (PDTs) of hACL-SCs and
hMCL-SCs. The PDT of hACL-SCs was markedly greater than that of
hMCL-SCs, indicating that hACL-SCs proliferated more slowly than
hMCL-SCs. The PDT results were obtained from passage 1 to passage 2
for both ACL-SCs and MCL-SCs from six donors (see Table 1).
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ties, including clonogenicity, self-renewal, and multi-
potency. Furthermore, both populations expressed stem
cell markers nucleostemin, SSEA-4, STRO-1, and Oct-4
as well as several CD markers (CD44 and CD90) for
mesenchymal stem cells (MSCs), but not those for
endothelial cells, hematopoietic stem cells, leukocytes,
or pericytes (CD31, CD34, CD45, and CD146). However,
it was found that a smaller proportion of hACL-SCs
expressed STRO-1, Oct-4, and CD44 compared to
hMCL-SCs. hACL-SCs also grew about 50% slower and
formed smaller and fewer colonies than hMCL-SCs.
Moreover, there was a marked difference in long-term
self-renewal capability between the two types of stem
cells: hACL-SCs became differentiated after only five
passages and two months in culture, whereas hMCL-
SCs maintained a nearly undifferentiated state even after
13 passages and the same culture time. Taken together,
Figure 4 The expression of two stem cell markers STRO-1 and Oct-4. As seen, hACL-SCs stained more weakly for STRO-1 than hMCL-SCs
(A). In addition, qRT-PCR showed that hACL-SCs expressed more than 300-fold lower levels of the STRO-1 gene than hMCL-SCs (B). Similarly,
fewer hACL-SCs expressed Oct-4 than hMCL-SCs (C), and Oct-4 gene expression by hACL-SCs was more than 7 times lower than that of hMCL-
SCs (D). Note that the results shown here were obtained from a 20-year-old male donor (see Table 1). The passage 1 cells were used in
immunostaining. (Bar: 100 μm).
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ligament specific stem cells that possess intrinsically dif-
ferent stem cell properties.
Nucleostemin, SSEA-4, STRO-1, and Oct-4 are four well
established stem cell markers used to confirm the stem
cell identity of hACL-SCs and hMCL-SCs in this study.
Nucleostemin is a nucleolar protein believed to act via p53
[25,26] and to be expressed by stem cells and cancer cells
but not terminally differentiated cells [26,27]. Thus, high
levels of nucleostemin expression by hACL-SCs and
hMCL-SCs in this study were indicative of proliferating,
self-renewing populations of ASCs. Like nucleostemin,
Oct-4 is also a nuclear protein expressed in embryonic
stem cells and carcinoma cell lines but not in differen-
tiated cells [28]. Oct-4 expression is lost during the pro-
cess of differentiation, and downregulation of Oct-4 is
thought to directly induce stem cell differentiation [29-31].
Figure 5 FACS analysis of hACL-SCs and hMCL-SCs. Both ligament stem cells were labeled with antibodies against human surface antigens
as listed. The maximum positive count for CD31, CD34, CD45, and CD146 was less than 2%, and there was no significant difference between
hACL-SCs and hMCL-SCs. However, large percentages (> 20%) of both ligament stem cells expressed CD44, CD90, and SSEA-4. The extent of
expression of these stem cell markers by hACL-SCs and hMCL-SCs was significantly different (see Table 3). Note that hACL-SCs and hMCL-SCs
(passages 1-2) used in the FACS analysis were obtained from four to six donors.
Table 3 FACS results of stem cell marker expression (%)
Marker SSEA-4 CD44 CD90
hACL-SC 20.1 ± 1.2 23.8 ± 5.8 89.1 ± 0.9
hMCL-SC 62.4 ± 6.0 48.7 ± 5.7 94.6 ± 1.3
P-value 0.002 0.006 0.002
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first identified as a marker that disappeared from human
teratocarcinoma cells as they differentiated [32,33], which
has since been recognized as a marker of human embryo-
nic stem cells [34] and mesenchymal stem cells [35] as
well. STRO-1 is a cell surface antigen found on bone
marrow mononuclear cells [36] capable of differentiating
down osteogenic [37,38], chondrogenic, and adipogenic
lines [39]. In addition, STRO-1 is expressed in human
periodontal ligament stem cells [40].
In addition to the stem cell markers above, we exam-
ined the expression of CD surface markers on hACL-SCs
and hMCL-SCs. Both ACL-SCs and MCL-SCs expressed
CD44 and CD90 (albeit the former exhibited a less extent
than the latter). Neither of the two types of ligament
stem cells expressed CD31, CD34, CD45, or CD146.
CD44 is a common MSC antigen [41,42] and is used as a
marker for bone marrow stem cells (BMSCs) [22]. CD90
is a fibroblast marker that has also been found on undif-
ferentiated human embryonic stem cells [43], and human
MSCs are consistently positive for both CD44 and CD90
[44-46]. Endothelial cell marker CD31 [47], hematopoie-
tic stem cell marker CD34 [48], pericyte marker CD146
[49], and leukocyte marker CD45 [50] were expressed by
neither hACL-SCs nor hMCL-SCs. These results provide
additional evidence that hACL-SCs and hMCL-SCs are
ASCs of mesenchymal origin.
A recent study by Cheng et al. looked into the possibility
of populations of stem cells existing in human ACLs [51].
It was shown that cells isolated from the ACL are
Figure 6 Self-renewal of hACL-SCs and hMCL-SCs. At passage 5, hACL-SCs had already become highly elongated in confluent culture, a
typical fibroblast phenotype (A). In contrast, even at passage 13, confluent hMCL-SCs remained cobblestone-like (B). Moreover, hACL-SCs no
longer expressed nucleostemin (C) or SSEA-4 (E) at passages > 5, whereas hMCL-SCs expressed both stem cell markers at passage 13 (D, F).
Note, however, that hMCL-SCs at this high passage exhibited a lesser degree of nucleostemin expression compared to the cells at passage 1
(see Figure 3). The results shown here were obtained from a male donor of 27 years old (see Table 1). (Bar: 100 μm).
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surface markers similar to MSCs, including CD73, CD90,
and CD105. The hACL-SCs isolated in our study displayed
similar characteristics as the ligament stem cells from
Cheng et al.’s study in terms of clonogenicity, multipo-
tency, and expression of stem cell markers CD44 and
CD90, but not CD34 or CD45. However, unlike this study,
the ACL samples used by Cheng et al. may not be normal
as they were collected from patients who had undergone
total knee arthroplasty.
Another study, in which ligament cells were derived
from young rabbits, found that the chondrogenic poten-
tial of ‘ligament-derived cells’ was greater for ACL cells
than MCL cells [24]. However, their study used a mixed
cell population rather than isolated stem cells as this
study did. Finally, tissue specific stem cells, such as
hACL-SCs and hMCL-SCs, have been found in various
tissues, including bone marrow [14], the periodontal
ligament [21], and human, mouse, and rabbit patellar
tendons [22,23], which are similar to extra-articular liga-
ments. In addition, rat flexor tendons were found to
contain stem cells [52]. Our group has also shown that
stem cells from rabbit patellar and Achilles tendons
express nucleostemin, Oct-4, and SSEA-4 [23]. The
same stem cell markers were found to be expressed on
both hACL-SCs and hMCL-SCs in this study.
While both hACL-SCs and hMCL-SCs were shown to
be ASCs, differences were also observed with regard to
their clonogenicity, self-renewal capacity, and differen-
tiation potential. We previously also found that stem
Figure 7 The expression of marker genes for adipogenesis (A), chondrogenesis (B), and osteogenesis (C). Compared to control cells,
these marker genes in both hACL-SCs and hMCL-SCs were highly upregulated when the ligament stem cells were grown in the respective
induction media. The RT-PCR results were obtained from a 29-year-old female donor (see Table 1). The results from another two donors were
similar (not shown). ALP, alkaline phosphatase; Coll. II, collagen type II; Cont., control; Differ., differentiated; LPL, lipoprotein lipase;.
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Page 10 of 14Figure 8 Histochemical staining of differentiated cells and semi-quantification of the extent of cell differentiation. Both hACL-SCs and
hMCL-SCs were able to differentiate into adipocytes (A), chondrocytes (C), and osteocytes (E), as shown by the accumulation of lipid droplets,
proteoglycans, and calcium deposits on cell surfaces. However, the extent of hACL-SC differentiation was less than that of hMCL-SC
differentiation, evidenced by smaller positive staining areas for adipogenesis (B), chondrogenesis (D), and osteogenesis (F) in hACL-SCs than in
hMCL-SCs. Note that each experiment was repeated three times using three different donors. (Bar: 100 μm).
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exhibit marked differences in colony formation and cell
proliferation rate [23]. Differences in gene profiles have
also been noted between MSCs derived from human
intra-articular (synovium, meniscus, and ACL) and
extra-articular sources (adipose, muscle, and bone) [42].
In addition, previous studies showed that ACL fibro-
blasts proliferate more slowly than their MCL counter-
parts [9,53]. These above studies, however, differ from
this study in that they used mixed cultures; in other
words, the cell population could include both stem cells
and residential adult cells (for example, ACL fibro-
blasts). Nevertheless, the finding in this study that
hACL-SCs proliferate much more slowly than hMCL-
SCs (Figure 2) is largely consistent with conclusions of
the above studies.
It is well recognized that injured ACLs have a low
healing capacity, whereas injured MCLs display a high
healing capacity [54-56]. Given that ASCs are the body’s
natural reservoir for replenishing pools of specialized
cells that have been damaged in tissue injury, we suggest
that the differential characteristics of hACL-SCs and
hMCL-SCs found in this study may also contribute to
their respective ligaments’ differential healing capacities.
Specifically, our data seem to indicate that hACL-SCs
lose their ‘stemness’ earlier than hMCL-SCs. This may
contribute to non-healing of injured ACLs as the hACL-
SCs may have lost their ability to self-renew during the
healing process; as a result, few cells will be available for
repair of the injured ACLs. On the other hand, because
of their superior capability of self-renewal, hMCL-SCs
can continuously supply cells to effectively repair injured
MCLs.
Besides the inherent lower stem cell capacity of
hACL-SCs, blood flow, an ‘external’ factor, is known to
b el o w e ri nt h eA C Lt h a ni nt h eM C Li nb o t hi n t a c t
and injured states. As a result, fewer nutrients will be
available to hACL-SCs compared to hMCL-SCs. There-
fore, again a smaller number of hACL-SCs and their
progeny cells will be produced compared to hMCL-SCs.
The finding that the hACL contains ASCs may enable
one to devise a new tissue engineering approach for
repair of injured hACLs. This could be done by using
small portions of ligaments to isolate and expand
hACL-SCs in vitro and then implanting the cells into
the injured ACL. On the other hand, while the injured
MCL heals spontaneously, the quality of the healed tis-
sue is still inferior with scar formation [57]. This is true
even with implantation of natural scaffolding materials
[58,59]. Therefore, hMCL-SCs may also be used as a
source for cellular-based therapies to restore the struc-
ture and function of the injured MCL.
Several comments are now in place regarding the
proper interpretation of the results of this study. First,
we used local application of trypsin to isolate stem cell
colonies in cultures. Such a technique may be subject to
contamination of a small number of ligament fibroblasts;
in other words, the stem cell populations used in this
study may not be pure. Second, there is an apparent dif-
ference in the results of stem cell marker expression
between immunocytochemistry (Figure 3) and FACS
analysis (Table 3). The difference may be caused by the
different passages of cells and the number of donors
used in the two different methods. For immunostaining
we used hACL-SCs and hMCL-SCs at passage 1 from a
26 year old donor, but for FACS analysis, passages 2 to
3 from six donors were used and the results were repre-
sented by mean ± SD. Third, hACL-SCs and hMCL-SCs
were found to express low levels of non-tenocyte related
genes, including PPARg, LPL, Sox-9, collagen II, and
Runx-2, even without differentiation induction media.
T h e r ea r et w op o s s i b l er e a s o n sf o rt h i s .W h i l et h el i g a -
ments used in our experiments were limited at grade 0
(normal), the donors might have slight degenerative
changes in their ACL and MCL ligaments. Additionally,
there is a possibility that a small population of stem
cells that somehow had differentiated towards non-
fibroblasts was present in cultures.
Conclusions
We show in this study that while both hACL-SCs and
hMCL-SCs exhibited clonogenicity, self-renewal, and
multi-differentiation potential, the three universal char-
acteristics of ASCs, hACL-SCs differed from hMCL-SCs
in that hACL-SCs expressed a much lower level of
STRO-1 and Oct-4, two stem cell marker genes. More-
over, compared to hMCL-SCs, hACL-SCs exhibited a
lower capacity for colony formation, slower proliferation,
a shorter period of self-renewal capability, and a lower
extent of multidifferentiation potential. As ASCs are
responsible for repair and regeneration of injured tis-
sues, we suggest that the differences in the properties of
the two ligaments’ stem cells may contribute to the dif-
ferential healing capacities of injured ACLs and MCLs
observed clinically.
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